Deal Intelligence Blog

Insights for Deal Professionals

Data-driven analysis backed by 1,400+ primary-sourced biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.

356 articles

All Buyer Intelligence Deal Analysis Market Trend Deal Trends How Much Comparison Industry Analysis Market Analysis Negotiation Strategy Deal Strategy

FeaturedMarket Analysis

Oncology M&A Benchmarking 2026: ADC Deal Comparisons, Phase-Stratified Analysis, and Strategic Outlook

Oncology remains the dominant therapeutic area for biopharma M&A, with ADCs driving the largest transactions. This comprehensive benchmarking report analyzes deal structures across clinical stages, models returns under uncertainty, and identifies which pharma companies still need ADC franchises.

April 7, 202610 min read

Read article

Market Analysis articles

Market Analysis9 min read

The GLP-1 Revolution: Obesity Drug Deal Landscape in 2026

The obesity drug market has transformed biopharma deal-making. From dual incretins to oral GLP-1 formulations, we analyze how the metabolic deal landscape is evolving in 2026.

Mar 14, 2026Read article

Benchmark Your Next Deal

Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,400+ primary-sourced biopharma transactions.

Try Solidus